EICHOR
● Recruiting
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Condition: Small Cell Lung Cancer Extensive Stage · Sponsor: Merck Sharp & Dohme LLC
About this study
Researchers are looking for new ways to treat extensive-stage small cell lung cancer (ES-SCLC). ES-SCLC is a type of lung cancer that has spread throughout the lung, to the other lung, or to other parts of the body. A standard (usual) treatment for ES-SCLC uses both chemotherapy and immunotherapy. * Chemotherapy is a treatment that works to destroy cancer cells or stop them from growing. * Immunotherapy is a treatment that helps the immune system fight cancer. Gocatamig and I-DXd (short for ifinatamab deruxtecan) are study medicines. Researchers want to know if giving gocatamig and I-DXd together can treat ES-SCLC. Researchers will also look at giving the study medicines with standard treatment. Gocatamig is a T-cell engager therapy. I-DXd is an antibody drug conjugate. * T-cell engager therapy is a certain type of immunotherapy that uses T-cells to find and destroy cancer cells. * A T-cell is a type of white blood cell, which are cells that help the body fight infection. * An antibody drug conjugate (ADC) is a treatment that attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of combining gocatamig and I-DXd and if people tolerate them together * If people who receive gocatamig and I-DXd have ES-SCLC respond, which means the cancer gets smaller or goes away
This description comes directly from the study's public registry record.
Talk to the study team
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
Locations (45)
| Providence Medical Foundation ( Site 0124) | Santa Rosa, California, United States | Recruiting |
| University of Colorado, Anschutz Cancer Pavilion ( Site 0125) | Aurora, Colorado, United States | Recruiting |
| Orlando Health Cancer Institute ( Site 0108) | Orlando, Florida, United States | Recruiting |
| Saint Elizabeth Medical Center Edgewood ( Site 0112) | Edgewood, Kentucky, United States | Recruiting |
| Washington University School of Medicine ( Site 0134) | St Louis, Missouri, United States | Recruiting |
| John Theurer Cancer Center at Hackensack University Medical Center ( Site 0101) | Hackensack, New Jersey, United States | Recruiting |
| Providence Cancer Institute, Franz Clinic - Eastside ( Site 0107) | Portland, Oregon, United States | Recruiting |
| Avera Cancer Institute- Research ( Site 0104) | Sioux Falls, South Dakota, United States | Recruiting |
| The University of Tennessee Medical Center ( Site 0120) | Knoxville, Tennessee, United States | Recruiting |
| Lt. Col. Luke Weathers, Jr. VA Medical Center ( Site 0133) | Memphis, Tennessee, United States | Recruiting |
| SCRI Oncology Partners ( Site 7000) | Nashville, Tennessee, United States | Recruiting |
| Houston Methodist Hospital - Houston Methodist Neal Cancer Center ( Site 0113) | Houston, Texas, United States | Recruiting |
+ 33 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07227597